Welcome to the INA-RESPOND public website.
Current and expanding infectious disease profile in Indonesia warrants a sense of urgency and mandates that research be a priority to guide the management and prevention of disease to reduce morbidity and mortality. The purpose of Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is to bring together clinical and academic medical institutions to develop a robust collaborative infectious disease research network.
By: Aly Diana Anything quantum scares me—like, totally scares me. But lately, I’ve decided that it’s time to explore things that scare me and try to understand them, hoping they become less terrifying. Spoiler alert: it doesn’t make things any less scary. Instead, it turns into this wild ride of “scary but interesting.” So here
Read moreBy: Edrick Purnomo Putra Nowadays, difficulty in sleeping or sleeping disorders are highly prevalent, especially in adults. One of the most common types of sleeping disorders is insomnia, and it is estimated that one-third of the global population suffers from symptoms of insomnia. Insomnia is also more prevalent in older adults, females, and individuals with
Read moreBy: Restu Amalia Mukti, Adhella Menur Cervical cancer has a significant impact on women and families in Indonesia, with over 103 million women aged 15 and older at risk. It is the second most common cancer among women after breast cancer, with approximately 36,964 new cases diagnosed annually. Alarmingly, around 70% of cases are detected
Read moreBy: Erni, Adhella Menur The mumps outbreak in Indonesia The earliest description of mumps as a disease dates back to the 5th century BC by Hippocrates. One notable passage describes: “Swellings appeared about the ears, in many on either side, and in the greatest number on both sides. They were of a lax, large, diffused
Read moreBy: Aly Diana I have never considered myself a gamer, but I was thrilled to discover that a mini-game embedded in Borderlands 3 is reaching its audience—scientists and non-scientists alike—to advance science. This idea struck me as nothing short of brilliant: low cost, high yield, and impactful on a massive scale. During this discovery period,
Read moreBy: Adhella Menur As a member of the INA-RESPOND Science team, I am thrilled with the acceptance of the first publication from our HIV study, entitled “A Prospective Observational Cohort Study of HIV Infection in Indonesia: Baseline Characteristics and One-Year Mortality” in the BMC Infectious Dis-eases journal. This paper provides valuable evidence for Indonesia and
Read moreBy: Meity Siahaan, Dedy Hidayat On December 4-5, 2024, a delegation from the Indonesian Ministry of Health (MoH) visited the United States National Institutes of Health (NIH) to strengthen existing collaborations and explore new opportunities in health research. This visit was an important step in strengthening bilateral cooperation in clinical research and capacity building between
Read moreBy: Aaron Neal INA-RESPOND has much to celebrate over the past year, and much to be excited for in 2025. Highlights from 2024 include the completion of the InVITE study, presentations at the annual Re-PORT tuberculosis (TB) meeting in Brazil, and the acceptance of key publications from HIV study (INA-PROACTIVE) and TB study (TRIPOD). Despite
Read moreBy: INA-RESPOND NSC Members and Secretariat New Year, New Hope! To move forward with strength, we must first reflect on the journey that has brought us here. Over the past 14 years, INA-RESPOND has grown into a center of excellence in infectious disease research in Indonesia. This achievement would not have been possible with-out the
Read moreTo collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
